Healthcare
Xenon Pharmaceuticals Inc.(XENE)
Live Price
Offline$52.91
-0.55% today
1Y Change
+66.40%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $4.53B
- Revenue Growth
- 0.0%
- EPS Growth
- -44.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xenon Pharmaceuticals Inc. (XENE) is a Healthcare stock with a market cap of $4.53B and listed on NASDAQ. The stock last traded around $52.91 and up 66.4% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -44.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -44.9%, free cash flow -51.7% with operating margin -4974.3% and ROIC -39.6%. Valuation already assumes a fairly strong business story at price/sales 604.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XENE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-4974.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -44.9%, with operating margin around -4974.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 10, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +0.0% | +0.8% | +0.0% | -7.6% |
2026 Feb 26, 2026 | -9.2% | -3.8% | -6.4% | +23.6% |
2025 Nov 3, 2025 | +0.9% | -4.9% | -6.6% | +4.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XENE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XENE Max Drawdown
-18.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XENE and SPY.
Company Overview
Xenon Pharmaceuticals Inc.
NASDAQ Global Market
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Leadership
- Andrea DiFabio
- IPO Date
- Nov 5, 2014
- Employees
- 316
- Street Address
- 3650 Gilmore Way
- Mailing
- Burnaby, BC, V5G 4W8
- Region
- Burnaby, BC, CA
- Reporting Currency
- USD
- Investor Line
- 16044843300
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 604.2
- Price/Book
- 7.8
Growth
- Revenue
- 0.0%
- EPS
- -44.9%
- Free Cash Flow
- -51.7%
Profitability
- Gross Margin
- -944.0%
- Operating Margin
- -4974.3%
- Net Margin
- -4612.1%
- ROE
- -55.8%
- ROIC
- -39.6%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 13.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.